SrasV1, PascalFrancis, Curation, bibRecord, 000397

Evaluation of a recombinant nucleocapsid protein-based assay for anti-SARS-CoV IgG detection

Identifieur interne : 000397 ( PascalFrancis/Curation ); précédent : 000396; suivant : 000398

Evaluation of a recombinant nucleocapsid protein-based assay for anti-SARS-CoV IgG detection

Auteurs : Paul K. S. Chan [Hong Kong] ; Esther Y. M. Liu [Hong Kong] ; Danny T. M. Leung [Hong Kong] ; Jo L. K. Cheung [Hong Kong] ; C. H. Ma [Hong Kong] ; Frankie C. H. Tam [Hong Kong] ; Mamie Hui [Hong Kong] ; John S. Tam [Hong Kong] ; PAK LEONG LIM [Hong Kong]

Source :

Journal of medical virology [ 0146-6615 ] ; 2005.

RBID : Pascal:05-0458730

Descripteurs français

Pascal (Inist)
- Coronavirus, Protéine recombinante, Nucléocapside, IgG, Détection, Diagnostic, Méthode immunoenzymatique, Enzyme, Sérologie, Syndrome respiratoire aigu sévère.
Wicri :
- topic : Enzyme.

English descriptors

KwdEn :
- Coronavirus, Detection, Diagnosis, Enzyme, Enzyme immunoassay, IgG, Nucleocapsid, Recombinant protein, Serology, Severe acute respiratory syndrome.

Abstract

A high throughput accurate assay for anti-SARS-CoV IgG detection is needed for large-scale epidemiological studies. The evaluation of a commercial recombinant nucleocapsid protein-based microtitre plate enzyme immunoassay, ELISARS is described. The results on 150 sera from SARS patients and 450 sera from non-SARS controls showed that this assay had a high level of sensitivity (96.2% for late serum samples) and specificity (97.8%). The performance and setup of this assay fulfills the requirement as a screening test for large-scale studies. A vast majority of SARS patients developed antibodies against the nucleocapsid protein. In some patients (10/45), a high level of anti-nucleocapsid antibody appeared very early in the course of the illness. In contrast, a minority (4 of 105 patients) never developed these antibodies. The implication of differences in antibody response to the nucleocapsid protein deserves further investigation.

A01	`01`	`1`		`@0 0146-6615`
A02	`01`			`@0 JMVIDB`
A03		`1`		`@0 J. med. virol.`
A05				`@2 75`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Evaluation of a recombinant nucleocapsid protein-based assay for anti-SARS-CoV IgG detection`
A11	`01`	`1`		`@1 CHAN (Paul K. S.)`
A11	`02`	`1`		`@1 LIU (Esther Y. M.)`
A11	`03`	`1`		`@1 LEUNG (Danny T. M.)`
A11	`04`	`1`		`@1 CHEUNG (Jo L. K.)`
A11	`05`	`1`		`@1 MA (C. H.)`
A11	`06`	`1`		`@1 TAM (Frankie C. H.)`
A11	`07`	`1`		`@1 HUI (Mamie)`
A11	`08`	`1`		`@1 TAM (John S.)`
A11	`09`	`1`		`@1 PAK LEONG LIM`
A14	`01`			`@1 Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital @2 Shatin, New Territories @3 HKG @Z 1 aut. @Z 7 aut. @Z 8 aut.`
A14	`02`			`@1 Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital @2 Shatin, New Territories @3 HKG @Z 1 aut. @Z 2 aut. @Z 4 aut. @Z 7 aut. @Z 8 aut.`
A14	`03`			`@1 Clinical Immunology Unit, The Chinese University of Hong Kong, Prince of Wales Hospital @2 Shatin, New Territories @3 HKG @Z 3 aut. @Z 5 aut. @Z 6 aut. @Z 9 aut.`
A20				`@1 181-184`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 17422 @5 354000127052660010`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 24 ref.`
A47	`01`	`1`		`@0 05-0458730`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of medical virology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 A high throughput accurate assay for anti-SARS-CoV IgG detection is needed for large-scale epidemiological studies. The evaluation of a commercial recombinant nucleocapsid protein-based microtitre plate enzyme immunoassay, ELISARS is described. The results on 150 sera from SARS patients and 450 sera from non-SARS controls showed that this assay had a high level of sensitivity (96.2% for late serum samples) and specificity (97.8%). The performance and setup of this assay fulfills the requirement as a screening test for large-scale studies. A vast majority of SARS patients developed antibodies against the nucleocapsid protein. In some patients (10/45), a high level of anti-nucleocapsid antibody appeared very early in the course of the illness. In contrast, a minority (4 of 105 patients) never developed these antibodies. The implication of differences in antibody response to the nucleocapsid protein deserves further investigation.
C02	`01`	`X`		`@0 002A05C10`
C02	`02`	`X`		`@0 002B05C02J`
C02	`03`	`X`		`@0 002A05C08`
C03	`01`	`X`	`FRE`	`@0 Coronavirus @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 Coronavirus @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 Coronavirus @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 Protéine recombinante @5 05`
C03	`02`	`X`	`ENG`	`@0 Recombinant protein @5 05`
C03	`02`	`X`	`SPA`	`@0 Proteína recombinante @5 05`
C03	`03`	`X`	`FRE`	`@0 Nucléocapside @5 06`
C03	`03`	`X`	`ENG`	`@0 Nucleocapsid @5 06`
C03	`03`	`X`	`SPA`	`@0 Nucleocápside @5 06`
C03	`04`	`X`	`FRE`	`@0 IgG @5 07`
C03	`04`	`X`	`ENG`	`@0 IgG @5 07`
C03	`04`	`X`	`SPA`	`@0 IgG @5 07`
C03	`05`	`X`	`FRE`	`@0 Détection @5 08`
C03	`05`	`X`	`ENG`	`@0 Detection @5 08`
C03	`05`	`X`	`SPA`	`@0 Detección @5 08`
C03	`06`	`X`	`FRE`	`@0 Diagnostic @5 09`
C03	`06`	`X`	`ENG`	`@0 Diagnosis @5 09`
C03	`06`	`X`	`SPA`	`@0 Diagnóstico @5 09`
C03	`07`	`X`	`FRE`	`@0 Méthode immunoenzymatique @5 10`
C03	`07`	`X`	`ENG`	`@0 Enzyme immunoassay @5 10`
C03	`07`	`X`	`SPA`	`@0 Método inmunoenzimático @5 10`
C03	`08`	`X`	`FRE`	`@0 Enzyme @2 FE @5 11`
C03	`08`	`X`	`ENG`	`@0 Enzyme @2 FE @5 11`
C03	`08`	`X`	`SPA`	`@0 Enzima @2 FE @5 11`
C03	`09`	`X`	`FRE`	`@0 Sérologie @5 12`
C03	`09`	`X`	`ENG`	`@0 Serology @5 12`
C03	`09`	`X`	`SPA`	`@0 Serología @5 12`
C03	`10`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 14`
C03	`10`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 14`
C03	`10`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 14`
C07	`01`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`04`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 13`
C07	`04`	`X`	`ENG`	`@0 Respiratory disease @5 13`
C07	`04`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 13`
C07	`05`	`X`	`FRE`	`@0 Virose`
C07	`05`	`X`	`ENG`	`@0 Viral disease`
C07	`05`	`X`	`SPA`	`@0 Virosis`
C07	`06`	`X`	`FRE`	`@0 Infection`
C07	`06`	`X`	`ENG`	`@0 Infection`
C07	`06`	`X`	`SPA`	`@0 Infección`
C07	`07`	`X`	`FRE`	`@0 Poumon pathologie @5 16`
C07	`07`	`X`	`ENG`	`@0 Lung disease @5 16`
C07	`07`	`X`	`SPA`	`@0 Pulmón patología @5 16`
N21				`@1 325`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000593

Links to Exploration step

Pascal:05-0458730

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Evaluation of a recombinant nucleocapsid protein-based assay for anti-SARS-CoV IgG detection</title>
<author><name sortKey="Chan, Paul K S" sort="Chan, Paul K S" uniqKey="Chan P" first="Paul K. S." last="Chan">Paul K. S. Chan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Liu, Esther Y M" sort="Liu, Esther Y M" uniqKey="Liu E" first="Esther Y. M." last="Liu">Esther Y. M. Liu</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Leung, Danny T M" sort="Leung, Danny T M" uniqKey="Leung D" first="Danny T. M." last="Leung">Danny T. M. Leung</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Immunology Unit, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Cheung, Jo L K" sort="Cheung, Jo L K" uniqKey="Cheung J" first="Jo L. K." last="Cheung">Jo L. K. Cheung</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Ma, C H" sort="Ma, C H" uniqKey="Ma C" first="C. H." last="Ma">C. H. Ma</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Immunology Unit, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Tam, Frankie C H" sort="Tam, Frankie C H" uniqKey="Tam F" first="Frankie C. H." last="Tam">Frankie C. H. Tam</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Immunology Unit, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Hui, Mamie" sort="Hui, Mamie" uniqKey="Hui M" first="Mamie" last="Hui">Mamie Hui</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Tam, John S" sort="Tam, John S" uniqKey="Tam J" first="John S." last="Tam">John S. Tam</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Pak Leong Lim" sort="Pak Leong Lim" uniqKey="Pak Leong Lim" last="Pak Leong Lim">PAK LEONG LIM</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Immunology Unit, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0458730</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0458730 INIST</idno>
<idno type="RBID">Pascal:05-0458730</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000593</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000397</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Evaluation of a recombinant nucleocapsid protein-based assay for anti-SARS-CoV IgG detection</title>
<author><name sortKey="Chan, Paul K S" sort="Chan, Paul K S" uniqKey="Chan P" first="Paul K. S." last="Chan">Paul K. S. Chan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Liu, Esther Y M" sort="Liu, Esther Y M" uniqKey="Liu E" first="Esther Y. M." last="Liu">Esther Y. M. Liu</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Leung, Danny T M" sort="Leung, Danny T M" uniqKey="Leung D" first="Danny T. M." last="Leung">Danny T. M. Leung</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Immunology Unit, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Cheung, Jo L K" sort="Cheung, Jo L K" uniqKey="Cheung J" first="Jo L. K." last="Cheung">Jo L. K. Cheung</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Ma, C H" sort="Ma, C H" uniqKey="Ma C" first="C. H." last="Ma">C. H. Ma</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Immunology Unit, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Tam, Frankie C H" sort="Tam, Frankie C H" uniqKey="Tam F" first="Frankie C. H." last="Tam">Frankie C. H. Tam</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Immunology Unit, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Hui, Mamie" sort="Hui, Mamie" uniqKey="Hui M" first="Mamie" last="Hui">Mamie Hui</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Tam, John S" sort="Tam, John S" uniqKey="Tam J" first="John S." last="Tam">John S. Tam</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Pak Leong Lim" sort="Pak Leong Lim" uniqKey="Pak Leong Lim" last="Pak Leong Lim">PAK LEONG LIM</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Immunology Unit, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of medical virology</title>
<title level="j" type="abbreviated">J. med. virol.</title>
<idno type="ISSN">0146-6615</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of medical virology</title>
<title level="j" type="abbreviated">J. med. virol.</title>
<idno type="ISSN">0146-6615</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Coronavirus</term>
<term>Detection</term>
<term>Diagnosis</term>
<term>Enzyme</term>
<term>Enzyme immunoassay</term>
<term>IgG</term>
<term>Nucleocapsid</term>
<term>Recombinant protein</term>
<term>Serology</term>
<term>Severe acute respiratory syndrome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Coronavirus</term>
<term>Protéine recombinante</term>
<term>Nucléocapside</term>
<term>IgG</term>
<term>Détection</term>
<term>Diagnostic</term>
<term>Méthode immunoenzymatique</term>
<term>Enzyme</term>
<term>Sérologie</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Enzyme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A high throughput accurate assay for anti-SARS-CoV IgG detection is needed for large-scale epidemiological studies. The evaluation of a commercial recombinant nucleocapsid protein-based microtitre plate enzyme immunoassay, ELISARS is described. The results on 150 sera from SARS patients and 450 sera from non-SARS controls showed that this assay had a high level of sensitivity (96.2% for late serum samples) and specificity (97.8%). The performance and setup of this assay fulfills the requirement as a screening test for large-scale studies. A vast majority of SARS patients developed antibodies against the nucleocapsid protein. In some patients (10/45), a high level of anti-nucleocapsid antibody appeared very early in the course of the illness. In contrast, a minority (4 of 105 patients) never developed these antibodies. The implication of differences in antibody response to the nucleocapsid protein deserves further investigation.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0146-6615</s0>
</fA01>
<fA02 i1="01"><s0>JMVIDB</s0>
</fA02>
<fA03 i2="1"><s0>J. med. virol.</s0>
</fA03>
<fA05><s2>75</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Evaluation of a recombinant nucleocapsid protein-based assay for anti-SARS-CoV IgG detection</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CHAN (Paul K. S.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LIU (Esther Y. M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>LEUNG (Danny T. M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CHEUNG (Jo L. K.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MA (C. H.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>TAM (Frankie C. H.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>HUI (Mamie)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>TAM (John S.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>PAK LEONG LIM</s1>
</fA11>
<fA14 i1="01"><s1>Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Clinical Immunology Unit, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>181-184</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>17422</s2>
<s5>354000127052660010</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>24 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0458730</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of medical virology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>A high throughput accurate assay for anti-SARS-CoV IgG detection is needed for large-scale epidemiological studies. The evaluation of a commercial recombinant nucleocapsid protein-based microtitre plate enzyme immunoassay, ELISARS is described. The results on 150 sera from SARS patients and 450 sera from non-SARS controls showed that this assay had a high level of sensitivity (96.2% for late serum samples) and specificity (97.8%). The performance and setup of this assay fulfills the requirement as a screening test for large-scale studies. A vast majority of SARS patients developed antibodies against the nucleocapsid protein. In some patients (10/45), a high level of anti-nucleocapsid antibody appeared very early in the course of the illness. In contrast, a minority (4 of 105 patients) never developed these antibodies. The implication of differences in antibody response to the nucleocapsid protein deserves further investigation.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C10</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02J</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002A05C08</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Protéine recombinante</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Recombinant protein</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Proteína recombinante</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Nucléocapside</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nucleocapsid</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Nucleocápside</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>IgG</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>IgG</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>IgG</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Détection</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Detection</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Detección</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Diagnostic</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Diagnosis</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Diagnóstico</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Méthode immunoenzymatique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Enzyme immunoassay</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Método inmunoenzimático</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Sérologie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Serology</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Serología</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>13</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>13</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>13</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>16</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>16</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>16</s5>
</fC07>
<fN21><s1>325</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000397 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000397 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:05-0458730
   |texte=   Evaluation of a recombinant nucleocapsid protein-based assay for anti-SARS-CoV IgG detection
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Evaluation of a recombinant nucleocapsid protein-based assay for anti-SARS-CoV IgG detection

Evaluation of a recombinant nucleocapsid protein-based assay for anti-SARS-CoV IgG detection

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri